A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation

NCT ID: NCT02833077

Last Updated: 2020-07-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

221 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-28

Study Completion Date

2018-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a safety and effectiveness study of JUVÉDERM VOLUMA XC injectable gel for chin augmentation to correct volume deficit in chin retrusion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chin Retrusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

JUVÉDERM VOLUMA® XC

JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.

Group Type EXPERIMENTAL

JUVÉDERM VOLUMA® XC

Intervention Type DEVICE

JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.

No Treatment then JUVÉDERM VOLUMA® XC

No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.

Group Type OTHER

JUVÉDERM VOLUMA® XC

Intervention Type DEVICE

JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JUVÉDERM VOLUMA® XC

JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chin retrusion
* In good general health

Exclusion Criteria

* Permanent facial implants on the face and/or neck
* Received fat injections below the nose
* Tattoos, piercings, beard, mustache, and/or scars on the face below the nose
* Received semi-permanent dermal fillers in the chin or jaw line in the last 3 years
* Undergone dermal filler injections or had any surgery in the chin or jaw area in the last 2 years
* Received dermal filler injections in the lips or in the mouth area in the last 12 months
* Undergone mesotherapy or cosmetic treatment (e.g., laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, liposuction, lipolysis, or other ablative procedures) anywhere in the face or neck in the last 6 months
* Received botulinum toxin treatment below the nose in the last 6 months
Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergan

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrew Schumacher

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.

San Diego, California, United States

Site Status

Skin Research Institute

Coral Gables, Florida, United States

Site Status

Baumann Cosmetic and Res. Institute

Miami Beach, Florida, United States

Site Status

Research Institute of the Southeast

West Palm Beach, Florida, United States

Site Status

DeNova Research

Chicago, Illinois, United States

Site Status

Callender Dermatology and Cosmetic Center

Glenn Dale, Maryland, United States

Site Status

SkinCare Physicians of Chestnut Hill

Chestnut Hill, Massachusetts, United States

Site Status

St Louis University Medical Center Dept. of Dermatology

St Louis, Missouri, United States

Site Status

Image Dermatology, PC

Montclair, New Jersey, United States

Site Status

Williams Plastic Surgery Specialists

Latham, New York, United States

Site Status

The Center for Dermatology, Cosmetics, & Laser Surgery

Mount Kisco, New York, United States

Site Status

Dermatology & Laser Center of Charleston Center for Clinical Research

Charleston, South Carolina, United States

Site Status

Nashville Centre for Laser and Facial Surgery

Nashville, Tennessee, United States

Site Status

Premier Clinical Research; Spokane Dermatology Clinic

Spokane, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Beer K, Kaufman-Janette J, Bank D, Biesman B, Dayan S, Kim W, Chawla S, Schumacher A. Safe and Effective Chin Augmentation With the Hyaluronic Acid Injectable Filler, VYC-20L. Dermatol Surg. 2021 Jan 1;47(1):80-85. doi: 10.1097/DSS.0000000000002795.

Reference Type DERIVED
PMID: 33347003 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Voluma-006

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.